6th Jan 2022 14:35
(Alliance News) - MGC Pharmaceuticals Ltd announced on Thursday it has received an import approval permit in India for its ArtemiC Rescue product, designed to benefit patients suffering from Covid-19.
The London and Perth-based plant-based medicine company said ArtemiC Rescue is a food supplement which has been proven in phase two clinical trials to help alleviate symptoms associated with moderate Covid-19.
The product was developed by MGC Pharma and its partner, Swiss PharmaCan AG. It has since undergone a small batch trial import and has passed all required regulations to enable the sale of the product in India.
MGC Pharma said the approval will further expand the global footprint for the sale and distribution of ArtemiC Rescue.
MGC Pharma added that it had received approval for the import permit with the assistance of a local partner, Carino Water Solutions & Energy LLP, who will continue to work with MGC Pharma and Swiss PharmaCan to seek further approvals in other countries.
CimertA, another of MGC Pharma's products for the treatment of patients with Covid-19, is seeking emergency use authorisation in India as well as US Food & Drug Administration approval.
Shares in MGC Pharmaceuticals were flat at 2.15 pence each on Thursday afternoon in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
MXC.L